[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 10 sources · 12 days · First seen · Last updated

KRAS mutation cancer research and therapy development

Overview

Research into KRAS-targeted cancer therapies has focused on identifying the biological mechanisms behind drug resistance and the varying efficacy of treatments across different mutation subtypes.

Initial studies using mouse models identified two primary ways tumors evade drugs: by increasing the number of KRAS gene copies to intensify growth signals, or by undergoing a cellular identity shift from adenocarcinomas to squamous cell carcinomas. This shift reduces dependency on KRAS, allowing growth through alternative signaling pathways.

Subsequent clinical developments have highlighted challenges in treating specific subtypes. While combining KRAS G12C inhibitors with anti-EGFR antibodies has improved progression-free survival in colorectal cancer, data from pan-RAS inhibitor trials show significant differences in response rates. For example, the drug daraxonrasib showed a 50% response rate for the G12V subtype but only 24% for the G12D subtype. This disparity has driven increased industry focus and investment into highly selective KRAS G12D inhibitors.

Entities

Kraš · Massachusetts Institute of Technology · Merck · Revolution Medicines · FDA

Timeline

  1. [HEALTH] 2 sources
    KRAS targeted therapies face subtype efficacy challenges

    New research and clinical data highlight the challenges of KRAS-targeted therapies, showing varying efficacy across mutation subtypes and driving interest in selective G12D inhibitors.

  2. [HEALTH] 8 sources
    KRAS mutation research reveals mechanisms of lung cancer drug resistance

    Studies on KRAS-mutated lung cancer reveal that tumors resist drugs by either increasing gene copies or changing cellular identity, highlighting the importance of precision medicine.

Sources

ciencias.uy · diario.mx · fmpowermax.com.ar · lacronicadebadajoz.elperiodicoextremadura.com · medical-tribune.co.jp · ocio.diariodemallorca.es · ocio.farodevigo.es · tiemposur.com.ar · tmtpost.com · web.eldia.es